Lexeo Therapeutics (LXEO) News Today $6.12 +0.10 (+1.66%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn SituationNovember 20 at 12:24 PM | finance.yahoo.comHC Wainwright Predicts Lower Earnings for Lexeo TherapeuticsNovember 20 at 2:09 AM | americanbankingnews.comLeerink Partnrs Has Bearish Outlook for LXEO FY2024 EarningsNovember 18 at 2:10 AM | americanbankingnews.comChardan Capital Brokers Decrease Earnings Estimates for LXEOLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at Chardan Capital reduced their FY2024 EPS estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings of ($November 18 at 2:08 AM | marketbeat.comWhat is HC Wainwright's Forecast for LXEO FY2024 Earnings?Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst M. Kapoor now forecastNovember 18 at 2:08 AM | marketbeat.comEquities Analysts Set Expectations for LXEO FY2024 EarningsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs cut their FY2024 earnings estimates for Lexeo Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($3.04) per share fNovember 18 at 2:08 AM | marketbeat.comLexeo Therapeutics Advances Cardiac Portfolio Amid Financial ReportNovember 15, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC CapitalNovember 15, 2024 | markets.businessinsider.comPromising Developments in Lexeo Therapeutics’ LX2006 Program Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comLexeo Therapeutics price target raised to $23 from $21 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comInsider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 2,500 Shares of StockNovember 14, 2024 | insidertrades.comHC Wainwright Increases Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $23.00HC Wainwright raised their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday.November 14, 2024 | marketbeat.comLexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comReviewing Lexeo Therapeutics (NASDAQ:LXEO) and Organovo (NASDAQ:ONVO)November 12, 2024 | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buNovember 3, 2024 | marketbeat.comCautious Optimism for Lexeo Therapeutics’ LX1001: Encouraging Interim Results and Investment PotentialOctober 31, 2024 | markets.businessinsider.comLexeo Therapeutics announces positive results from Phase 1/2 study of LX1001October 31, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO)HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price target on shares of Lexeo Therapeutics in a research note on Thursday.October 31, 2024 | marketbeat.comLexeo Therapeutics Sees Positive Results for Alzheimer's Disease TreatmentOctober 30, 2024 | marketwatch.comLexeo Therapeutics Reports Positive Interim Data From Phase 1/2 Study Of LX1001 In ADOctober 30, 2024 | markets.businessinsider.comLexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 30, 2024 | globenewswire.comNovo Holdings A S Sells 327,919 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Novo Holdings A S lessened its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,122,581 shares of the compOctober 27, 2024 | marketbeat.comLexeo Therapeutics' (LXEO) Buy Rating Reiterated at Chardan CapitalChardan Capital reissued a "buy" rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a report on Friday.October 25, 2024 | marketbeat.comLexeo Therapeutics: Promising Alzheimer’s Treatment Advances Drive Buy RatingOctober 25, 2024 | markets.businessinsider.comLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 ConferenceOctober 22, 2024 | markets.businessinsider.comLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 ConferenceOctober 22, 2024 | globenewswire.comRichard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) StockOctober 16, 2024 | insidertrades.comInsider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of StockLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.October 15, 2024 | marketbeat.comLexeo Therapeutics, Inc. (LXEO) Receives a Buy from Stifel NicolausOctober 10, 2024 | markets.businessinsider.comLarimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside PotentialOctober 6, 2024 | seekingalpha.comNovo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Novo Holdings A S reduced its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 11.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,450,500 shares of the company's stock after selling 187,798 shSeptember 30, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest UpdateLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,240,000 shares, a decrease of 36.1% from the August 15th total of 1,940,000 shares. Based on an average daily trading volume, of 303,700 shares, the short-interest ratio is presently 4.1 days. Approximately 5.7% of the company's shares are sold short.September 14, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by AnalystsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been given a consensus recommendation of "Buy" by the nine analysts that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the coSeptember 14, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 SharesLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the transaction, the chief executive officer now directly owns 120,695 shares of the company's stock, valued at $1,285,401.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website.September 11, 2024 | marketbeat.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesSeptember 5, 2024 | globenewswire.comShort Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Grows By 16.9%Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,940,000 shares, an increase of 16.9% from the July 31st total of 1,660,000 shares. Based on an average trading volume of 301,400 shares, the short-interest ratio is currently 6.4 days. Currently, 8.8% of the company's stock are short sold.September 1, 2024 | marketbeat.comLexeo Therapeutics, Inc. (LXEO)August 21, 2024 | finance.yahoo.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Buy" from BrokeragesShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given a consensus recommendation of "Buy" by the nine brokerages that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strongAugust 20, 2024 | marketbeat.comVanguard Group Inc. Has $7.55 Million Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Vanguard Group Inc. increased its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 15.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 481,755 shares of the company's stock after buying an additional 65,573 shares during the perioAugust 17, 2024 | marketbeat.comLexeo Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.46) Per Share (NASDAQ:LXEO)Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Chardan Capital issued their FY2025 EPS estimates for Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. Chardan Capital analyst G. Livshits anticipates that the companyAugust 16, 2024 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Issues Earnings ResultsLexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.64) earnings per share for the quarter, meeting the consensus estimate of ($0.64).August 14, 2024 | marketbeat.comBuy Rating for Lexeo Therapeutics Backed by Strong Finances and Promising Clinical TrialsAugust 14, 2024 | markets.businessinsider.comBuy Rating on Lexeo Therapeutics: Promising Clinical Advancements and Strategic FDA EngagementAugust 14, 2024 | markets.businessinsider.comHC Wainwright Trims Lexeo Therapeutics (NASDAQ:LXEO) Target Price to $21.00HC Wainwright reduced their price target on Lexeo Therapeutics from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Tuesday.August 13, 2024 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday.August 13, 2024 | marketbeat.comLexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsAugust 12, 2024 | globenewswire.comJanus Henderson Group PLC Boosts Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)Janus Henderson Group PLC increased its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 9.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,540,785 shares of the company's stock after pJuly 31, 2024 | marketbeat.comPromising Interim Clinical Trial Results Bolster Confidence in Lexeo Therapeutics’ Gene Therapy PotentialJuly 19, 2024 | markets.businessinsider.comLexeo Down Despite Upbeat Rare Disease Gene Therapy DataJuly 19, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs ForecastsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2024 earnings per share estimates for Lexeo Therapeutics in a research note issued to investors on Monday, July 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the coJuly 18, 2024 | marketbeat.com Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼-0.250.46▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼232▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Erasca News Today Autolus Therapeutics News Today Evolus News Today Pliant Therapeutics News Today Cronos Group News Today Cullinan Therapeutics News Today Prothena News Today Replimune Group News Today CARGO Therapeutics News Today Anavex Life Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
